POZN $7 getting a little early action
POZN POZEN: Discussions at AHS confirm Trexima safety - Jefferies (6.73 )
Jefferies says their discussions with investigators and GSK, coupled with additional long-term safety data at AHS, show no out-of-ordinary safety issues for Trexima. Furthermore, firm says that more safety information asked by the FDA could be relatively quickly resolved, perhaps without additional trials. Firm would buy POZN on its attractive risk/reward profile.
Market Data 
Markets 
AI
